SLC5A2 and hydrops fetalis: In the sacubitril-valsartan study, the eligibility assessment was based on the strict main criteria from the PARADIGM-HF trial resulting in few eligible patients in the real-world population compared to the SGLT2 inhibitors and faricimab studies.